Ann: 2019 Annual Report, page-16

Having finally had a chance to get through the report i think the highlight was pg 28 under 'outlook', it essentially says 'the company expects stronger results driven by Tolsura and Lexette' and then lists every other division (did i miss one?). It later adds 'in addition', before mentioning a number of cost improving initiatives and reductions for a number of divisions.

So, it looks like on top of a forecast improvement in earnings (~$525m FY19), in every division (is that right?), MYX is also forecasting a large reduction in costs across a number of divisions.

Based on the above those margins of ~50% are going to improve, and so to should the share price before the excitement of Nuvaring generic hits stores with E4/DRSP (a naturally derived estrogen, and the first estrogen launched in the US in about 50 years) really gets things going. Which investment bank was it that said they valued E4/DRSP at ~30c/share? Which is obviously on top of an improvement in MYX across the board.